[ Price : $8.95]
FDA approves Johnson & Johnsons Tremfya (guselkumab) for treating adults with moderately to severely active ulcerative colitis.[ Price : $8.95]
Gilead Sciences says data from a second pivotal Phase 3 clinical trial investigating its twice-yearly injectable lenacapavir show ...[ Price : $8.95]
GSK moves its mRNA seasonal influenza vaccine program into Phase 3 after reporting favorable Phase 2 data.[ Price : $8.95]
FDA publishes a guidance on submitting ANDA amendments under GDUFA 3.[ Price : $8.95]
Federal Register notice: FDA determines the regulatory review period for Cyclomedica Australias Technegas (technetium Tc 99m-label...[ Price : $8.95]
Federal Register notice: FDA determines the regulatory review period for Marinus Pharmaceuticals Ztalmy (ganaxolone), indicated fo...[ Price : $8.95]
CDERs Office of Prescription Drug Promotion cites AbbVie in a just-released untitled letter over its television direct-to-consumer...[ Price : $8.95]
FDA issues a strategy document on innovative manufacturing technologies with three action steps it will take.